May 20th 2022
Experts highlight remaining unmet needs in the management of radioiodine-refractory differentiated thyroid cancer and share their hopes for the future.
May 13th 2022
Before closing out their discussion on radioiodine-refractory DTC management, experts share practical advice for community physicians.
Shared insight on active surveillance practices for patients with radioiodine-refractory DTC and how disease factors play into selection of therapy at time of recurrence.
May 6th 2022
Reflecting on a real-world patient scenario of DTC, experts consider how they identify radioiodine-refractory disease and when they would initiate systemic therapy.
Expert Lori Wirth, MD, highlights key points from a second real-world patient scenario of radioiodine-refractory differentiated thyroid cancer.
April 29th 2022
Expert advice on addressing adverse events, particularly through dose holds or reduction, in patients on lenvatinib therapy for radioiodine-refractory DTC.
Shared insight on selecting appropriate patients for lenvatinib therapy in differentiated thyroid cancer, as well as optimizing dosing strategies in the context of clinical trial data.
April 22nd 2022
A brief discussion on where endocrinologists and oncologists respectively fit into the differentiated thyroid cancer treatment paradigm.
Reflecting on the first patient scenario of radioiodine-refractory DTC, experts share their considerations for optimally selecting and sequencing therapy in this setting.
April 15th 2022
Perspectives on the use of lenvatinib therapy to manage a patient with radioiodine-refractory DTC, preceding broader considerations for sequencing kinase inhibitor therapy.
Expert Marcia Brose, MD, details a clinical scenario wherein a patient is diagnosed with differentiated thyroid cancer and managed with surgical and radiotherapy.
February 3rd 2022
An overview of therapies in the pipeline for differentiated thyroid cancer and their potential effect on clinical decision-making.
Naifa L. Busaidy, MD, FACP, FACE, recognizes the importance of reassessing patients prior to considering a second-line therapy for differentiated thyroid cancer.
The role of BRAF inhibitors and checkpoint inhibitors in differentiated thyroid cancer, and potential considerations for using BRAF inhibition as redifferentiation therapy.
January 28th 2022
The rationale for targeting actionable mutations in differentiated thyroid cancer with RET and NTRK inhibitors.
Considerations regarding approaches to sequencing therapies for differentiated thyroid cancer.
January 21st 2022
An overview of the types of targeted drug classes available to treat differentiated thyroid cancer at various clinical stages.
Maria E. Cabanillas, MD, describes what triggers her to initiate therapy for differentiated thyroid cancer and variables that impact treatment choice.
January 4th 2022
Lori J. Wirth, MD, discusses the utility of tipifarnib in patients with head and neck cancer whose tumors harbor HRAS mutations.
November 5th 2021
Lori J. Wirth, MD, discusses the phase 3 LIBRETTO-531 trial of selpercatinib in patients with RET-mutant medullary thyroid cancer.